RhumbLine Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$504K	Buy	54,101 +256	+0.5%	+$2.23K	﹤0.01%	2609
2025 Q4	$404K	Sell	53,845 -10,334	-16%	-$105K	﹤0.01%	2796
2025 Q3	$558K	Sell	64,179 -1,779	-3%	-$10.6K	﹤0.01%	2626
2025 Q2	$245K	Sell	65,958 -4,845	-7%	-$17K	﹤0.01%	3114
2025 Q1	$229K	Sell	70,803 -2,628	-4%	-$12.4K	﹤0.01%	3040
2024 Q4	$409K	Buy	73,431 +3,675	+5%	+$28.8K	﹤0.01%	2794
2024 Q3	$754K	Sell	69,756 -3,177	-4%	-$52.7K	﹤0.01%	2422
2024 Q2	$1.53M	Buy	72,933 +9,062	+14%	+$227K	﹤0.01%	2023
2024 Q1	$2.03M	Buy	63,871 +3,950	+7%	+$101K	﹤0.01%	1909
2023 Q4	$1.21M	Buy	59,921 +1,472	+3%	+$19.4K	﹤0.01%	2154
2023 Q3	$744K	Buy	58,449 +9,461	+19%	+$158K	﹤0.01%	2372
2023 Q2	$885K	Buy	48,988 +1,487	+3%	+$27.4K	﹤0.01%	2360
2023 Q1	$817K	Buy	47,501 +58	+0.1%	+$1.13K	﹤0.01%	2219
2022 Q4	$1.05M	Buy	47,443 +2,070	+5%	+$32K	﹤0.01%	2106
2022 Q3	$365K	Buy	45,373 +3,788	+9%	+$34.3K	﹤0.01%	2637
2022 Q2	$290K	Buy	41,585 +6,488	+18%	+$63.1K	﹤0.01%	2773
2022 Q1	$531K	Buy	35,097 +4,382	+14%	+$68.8K	﹤0.01%	2400
2021 Q4	$674K	Buy	30,715 +6,177	+25%	+$151K	﹤0.01%	2384
2021 Q3	$662K	Buy	24,538 +15,031	+158%	+$429K	﹤0.01%	2425
2021 Q2	$229K	Buy	9,507 +3,651	+62%	+$112K	﹤0.01%	2887
2021 Q1	$254K	Buy	+5,856	New	+$259K	﹤0.01%	2755